Coverage options for promising technologies: Medicare's 'Coverage with evidence development'

Health Affairs

Volumn 25, Issue 5, 2006, Pages 1218-1230

  Tunis, Sean R ^a,b,c   Pearson, Steven D ^d  

^a Center for Medical Technology Policy   (United States)

^b Health Technology Center   (United States)

^c Coverage and Analysis Group ^*  (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOTECHNOLOGY; ECONOMICS; EVIDENCE BASED MEDICINE; GOVERNMENT REGULATION; HEALTH INSURANCE; HUMAN; MEDICAL TECHNOLOGY; MEDICARE; PHARMACEUTICS; REVIEW; UNITED STATES;

BIOMEDICAL TECHNOLOGY; BIOPHARMACEUTICS; BIOTECHNOLOGY; EVIDENCE-BASED MEDICINE; GOVERNMENT REGULATION; HUMANS; INSURANCE, PHARMACEUTICAL SERVICES; MEDICARE; UNITED STATES;

EID: 33749332084     PISSN: 02782715     EISSN: 02782715     Source Type: Journal    
DOI: 10.1377/hlthaff.25.5.1218     Document Type: Review

References (39)

1. Centers for Medicare and Medicaid Services, "National Coverage Determinationswith Data Collection as a Condition of Coverage: Coverage with Evidence Development," 12 July 2006, http://www.cms.hhs.gov/mcd/ ncpc_view_document.asp?id=8 (accessed 14 July 2006).
2. T. Carino et al., "Medicare's Coverage of Colorectal Cancer Drugs: A Case Study in Evidence Development and Policy," Health Affairs 25, no. 5 (2006): 1231-1239.
3. S.D. Pearson, J.E. Sabin, and E.J. Emmanuel, "Medical Necessity, Coverage Decisions, and Medical Policy," in No Margin, No Mission: Health Care Organizations and the Quest for Ethical Excellence (New York: Oxford University Press, 2003), 69-71;
4. and N. Daniels and J.E. Sabin, "Last Chance Therapies and Managed Care: Pluralism, Fair Procedures, and Legitimacy," Hastings Center Report 28, no. 2 (1998): 27-41.
5. S.J. Reiser, "Criteria for Standard versus Experimental Therapy," Health Affairs 13, no. 3 (1994): 127-136;
6. D.M. Eddy, "Investigational Treatments: How Strict Should We Be?" Journal of the American Medical Association 278, no. 3 (1997): 179-185;
7. and E.P. Steinberg, S. Tunis, and D. Shapiro, "Insurance Coverage for Experimental Technologies," Health Affairs 14, no. 4 (1995): 143-158.
8. A.M. Garber, "Evidence-based Coverage Policy," Health Affairs 20, no. 5 (2001): 62-82.
9. T. Carino, S. Sheingold, and S. Tunis, "Using Clinical Trials as a Condition of Coverage: Lessons from the National Emphysema Treatment Trial," Clinical Trials 1, no. 1 (2004): 108-114.
10. R.A. Rettig and W. Aubry, False Hope versus Evidence-based Medicine: Bone Marrow Transplantation and Breast Cancer (New York: Oxford University Press, forthcoming).
11. A. Fishman et al., "A Randomized Trial Comparing Lung-Volume-Reduction Surgery with Medical Therapy for Severe Emphysema," New England Journal of Medicine 348, no. 21 (2003): 2059-2073.
12. Carino et al., "Using Clinical Trials."
13. G. Kolata, "Medicare Says It Will Pay, but Patients Say 'No Thanks'," New York Times, 3 March 2006.
14. S.R. Tunis and J.L Kang, "Improvements in Medicare Coverage of New Technology," Health Affairs 20, no. 5 (2001): 83-85.
15. CMS, "Decision Memo for Pelvic Floor Electrical Stimulation for Urinary Incontinence (CAG-00021N)," 5 October 2000, http://www.cms.hhs.gov/ mcd/viewdecisionmemo.asp?id=61 (accessed 14 June 2006).
16. Food and Drug Administration, "Implementation of the FDA/HCFA Interagency Agreement regarding Reimbursement Categorization of Investigational Devices, September 15, 1995 (D95-2)," http://www.fda.gov/cdrh/d952.html (accessed 29 May 2006).
17. CMS, "Decision Memo for Percutaneous Transluminal Angioplasty (PTA) of the Carotid Artery Concurrent with Stenting (CAG-00085N)," 19 March 2001, http://www.cms.hhs.gov/mcd/viewdecisionmemo.asp?id=62 (accessed 14 June 2006).
18. CMS, "Decision Memo for Positron Emission Tomography (FDG) for Alzheimer's Disease/Dementia (CAG-0008N)," 16 April 2003, http://www.cms.hhs.gov/mcd/viewdecisionmemo.asp?id=64 (accessed 14 June 2006).
19. D.M. Matchar et al., Use of Positron Emission Tomography and Other Neuroimaging Techniques in the Diagnosis and Management of Alzheimer's Disease and Dementia, Task Order 7, 14 December 2001, http://www.cms.gov/coverage/ download/id64.pdf (accessed 14 June 2006).
20. R. Weiss, "A Tale of Politics: PET Scans' Change in Medicare Coverage," Washington Post, 14 October 2004.
21. CMS, "Decision Memo for Positron Emission Tomography (FDG) and Other Neuroimaging Devices for Suspected Dementia (CAG-00088R)," 15 September 2004, http://www.cms.hhs.gov/mcd/viewdecisionmemo.asp?id=104 (accessed 14 June 2006);
22. S.R. Tunis, D.B. Stryer, and C.M. Clancy, "Practical Clinical Trials: Increasing the Value of Clinical Research for Decision Making in Clinical and Health Policy," Journal of the American Medical Association 290, no. 12 (2003): 1624-1632;
23. and R.E. Glasgow et al., "Practical Clinical Trials for Translating Research to Practice: Design and Measurement Recommendations," Medical Care 43, no. 6 (2005): 551-557.
24. S.L. Kulasingam, G.P. Samsa, and D.B. Matchar, "Linking Dementia Research to Policy: An Example using Fluorodeoxyglucose Positron Emission Tomography for the Diagnosis of Alzheimer's Dementia and Mild Cognitive Impairment," American Journal of Alzheimer's Disease and Other Dementias 21, no. 2 (2006): 73-78.
25. R. Weiss, "Medicare to Cover Cardiac Device," Washington Post, 20 January 2005.
26. A. Kadish, "Prophylactic Defibrillator Implantation - Toward an Evidence-based Approach," New England Journal of Medicine 352, no. 3 (2005): 285-287.
27. M.B. McClellan and S.R. Tunis, "Medicare Coverage of ICDs," New England Journal of Medicine 352, no. 3 (2005): 222-224.
28. M.B. McClellan and S.R. Tunis, "Medicare Coverage of ICDs," New England Journal of Medicine 352, no. 3 (2005): 222-224. Ibid.
29. CMS, "Factors CMS Considers in Making a Determination of Coverage with Evidence Development" (Baltimore: CMS, April 2005).
30. "Factors CMS Considers in Making a Determination of Coverage with Evidence Development" Ibid., 2.
31. "Factors CMS Considers in Making a Determination of Coverage with Evidence Development" Ibid., 7.
32. G.P. Bagley and R. Maxwell, "Linking Medicare Coverage to Research Participation: Reasonable and Necessary?" 2005, http://www.medicarerxguide. com/MDRG/2005/200506_BagleyWLPwhitepaper.pdf (accessed 18 July 2006).
33. Letter from Mark Heeson, National Venture Capital Association, to Mark McClellan, CMS administrator, 6 June 2005, http://www.nvca.org/pdf/NVCA- CED_Comment_Ltr_6-6-05.pdf (accessed 2 August 2006).
34. U.E. Reinhardt, "An Information Infrastructure for the Pharmaceutical Market," Health Affairs 23, no. 1 (2004): 107-112;
35. and J. Kupersmith et al., "Creating a New Structure for Research on Health Care Effectiveness," Journal of Investigative Medicine 53, no. 2 (2005): 67-72.
36. S.R. Tunis, "A Clinical Research Strategy to Support Shared Decision Making," Health Affairs 24, no. 1 (2005): 180-184.
37. M. Rawlins, "In Pursuit of Quality: The National Institute of Clinical Excellence," Lancet 353, no. 9158 (1999): 1079-1082;
38. P.P. Glasziou, "Support for Trials of Promising Medications through the Pharmaceutical Benefits Scheme: A Proposal for a New Authority Category," Medical Journal of Australia 162, no. 1 (1995): 33-36;
39. and I. Chalmers, "Minimizing Harm and Maximizing Benefit during Innovation in Health Care: Controlled or Uncontrolled Experimentation?" Birth 13, no. 3 (1986): 155-164.